Diabetes drug may reduce cardiovascular risksNovember 14, 2006A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of Medicine. The study, led by Dr. Theodore Mazzone, professor of medicine at UIC, is posted online and will appear in the Dec. 6 print issue of JAMA. The results will also be presented at the American Heart Association scientific session Monday in Chicago. Patients with type 2 diabetes are known to have an increased risk of heart attack and other cardiovascular events. Some evidence suggests that a class of oral drugs used to treat type 2 diabetes called thiazolidinediones may be useful in reducing the progression of atherosclerosis, a thickening and hardening of the arteries that can lead to cardiac events. Mazzone and colleagues conducted a Chicago-area multicenter trial to test a potential new approach for slowing the thickening of artery walls in diabetic patients. They enrolled 462 racially and ethnically diverse adults with type 2 diabetes. The 289 men and 173 women, whose average age was 60, were randomly assigned to receive either pioglitazone (a thiazolidinedione sold as Actos), a drug that increases the body's sensitivity to insulin, or glimepiride (sold as Amaryl), another type of diabetes drug that stimulates the pancreas to make more insulin. Patients received a baseline ultrasound to measure the thickness of the lining and middle layers of the carotid arteries, which carry blood to the brain. The arteries' thickness is a marker for coronary atherosclerosis and a predictor of future heart attack. The patients were then evaluated at 24, 48 and 72 weeks to measure the progression of thickenening. "The less the thickening, and the slower the rate of thickening, the less risk of heart attack in general," said Mazzone. By the end of the study, patients taking pioglitazone had an artery thickness that decreased an average of 0.001 millimeters, while in those taking glimepiride it increased 0.012 millimeters. About 70 percent of all patients were able to complete the 72-week trial. The study, Mazzone said, showed that pioglitazone significantly slowed the thickening of the carotid artery wall compared to the other diabetes drug. "We showed this for both the average thickness of the wall, as well as the maximum thickness of the wall," he said. The beneficial effect of pioglitazone was uniform regardless of age, sex, duration of diabetes, blood pressure, blood cholesterol levels or blood glucose control. The study also monitored cardiovascular clinical events. There were four adverse events in the pioglitazone treated group, including three patients who required coronary revascularization. There were 10 adverse events in the glimepiride treated group, including eight who required coronary revascularization. "Additional data needs to be brought to bear," said Mazzone, "however this is very helpful for suggesting that pioglitazone could be a useful, novel approach for managing cardiovascular risk in patients with diabetes." University of Illinois at Chicago |
|||||||||||||||||||||
| Related Diabetes Current Events and Diabetes News Articles Flaxseed oil and osteoporosis Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health. Diabetes surgery summit consensus lays foundation for new field of medicine A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery. ESC to give talks on Diabetes in three cities in China As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou. New research shows versatility of amniotic fluid stem cells For the first time, scientists have demonstrated that stem cells found in amniotic fluid meet an important test of potential to become specialized cell types, which suggests they may be useful for treating a wider array of diseases and conditions than scientists originally thought. First reconstitution of an epidermis from human embryonic stem cells Stem cell research is making great strides. This is yet again illustrated by a study carried out by the I-STEM* Institute (I-STEM/ Inserm UEVE U861/AFM), published in the Lancet on 21 November 2009. The I-STEM team, directed by Marc Peschanski has just succeeded in recreating a whole epidermis from human embryonic stem cells. An atomic-level look at an HIV accomplice Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity. Scripps research scientists find new link between insulin and core body temperature A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature. Scientists find molecular trigger that helps prevent aging and disease Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease? Pivotal study for PSD502 -- the first potential treatment for premature ejaculation At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Night Beat, Overtime and a Disrupted Sleep Pattern Can Harm Officers' Health A police officer who works the night shift, typically from 8 p.m. to 4 a.m., already is at a disadvantage when it comes to getting a good "night's" sleep. More Diabetes Current Events and Diabetes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||